DMRA
The table below shows Damora Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$20.60M | -$2.44M | -$5.94M | -$9.13M | -$6.80M | -$14.15M |
| Capital expenditure | - | - | - | - | $43.00K | $65.00K |
| Investing cash flow | - | - | $5.65M | $1.37M | -$10.21M | -$74.63M |
| Dividends paid | - | - | - | - | - |
Damora Therapeutics, Inc. reported operating cash flow of -$6.73M for fiscal year 2025. That is up 63.9% from -$18.62M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from -$19.33M (FY 2019) to -$6.73M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $295.92M | - | - | $23.00K | - | - |